Clinical Cooperation Unit Nuclear Medicine
Prof. Dr. Uwe Haberkorn (in ch.)
DOTATOC-PET in a patient with metastasized neuroendocrine tumor.
The Clinical Cooperation Unit Nuclear Medicine is involved in multiple projects on topics such as the planning and follow up of chemo- or radiation therapy, pharmacokinetic modelling of dynamic PET data, identification of new peptides with high affinity for tumor disease; the establishment of new endoradiotherapy approaches based on peptides and antibodies; the development of alternate panning strategies with phage and ribosome display using recombinant proteins, membrane fractions and cells; the design of combination therapy with endoradiotherapy and chemo-, immuno- or radiation therapy; and the establishment of new treatments for non-iodine-concentrating thyroid carcinoma.
Selected Publications
Kratochwil C et al. (2010). Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC-PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res 16:2899-2905
Strauss LG et al. (2011). Shortened acquisition protocols for the quantitative assessment of the 2-tissue compartment mod-el using dynamic PET/CT 18F-FDG studies. J Nucl Med 52:379-385
Askoxylakis V et al. (2010). A New Peptide Ligand for Targeting Human Car-bonic Anhydrase IX, Identified through the Phage Display Technology. PLoS One 5:e15962.
Altmann A et al. (2010). Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275. Eur J Nucl Med Mol Imaging 37:2286-2297.
